• gregorum@lemm.ee
    link
    fedilink
    English
    arrow-up
    8
    ·
    edit-2
    1 year ago

    The FDA and HHS have already made their recommendations to reschedule. Now the DEA gets to weigh in, then there’s a period for public comment. After that, IIRC, the FDA makes a final decision. The current recommendation is to Schedule III from Schedule I.

    but that’s just for rescheduling on a federal level.

    edit: correction-- it’s the DEA who makes the ultimate decision.

    • TWeaK@lemm.ee
      link
      fedilink
      English
      arrow-up
      3
      arrow-down
      1
      ·
      1 year ago

      Thanks, that’s a good overview.

      Schedule III is still too harsh, imo, though.

      • gregorum@lemm.ee
        link
        fedilink
        English
        arrow-up
        3
        ·
        edit-2
        1 year ago

        agreed. Schedule IV or descheduling altogether would be most fitting. The fact that it’s a legitimate medication for many conditions and is still the subject of a great deal of research muddies the waters a bit, however.